Practice-Oriented Recommendations for Strain Matching and Delivery in Personalized Phage Therapy

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Nature Medicine  https://doi.org/10.1038/s41591-026-04654-6
Dr. Silvia Würstle et al.

Points

An international working group led by the German Society for Infectious Diseases developed the first consensus guidelines for personalized bacteriophage therapy published in Nature Medicine.
More than sixty practice recommendations were established by twenty professional societies and eighteen international experts to standardize phage selection manufacturing and clinical monitoring procedures.
Observational data from a Belgian case series showed clinical improvement in seventy seven percent of patients and bacterial clearance in sixty one percent following phage treatment.
Clinical programs at Frankfurt University Medical Center successfully treated ten patients using individualized phage regimens administered via intravenous inhalation or hydrogel formulations.
Authors concluded that standardized susceptibility testing and centralized registry documentation are essential prerequisites for safely incorporating personalized phage therapeutics into routine medical practice.

Summary

This study evaluated the clinical implementation framework for personalized bacteriophage therapy to address difficult-to-treat, multi-drug resistant bacterial infections. Published in Nature Medicine and led by the German Society for Infectious Diseases (DGI) alongside the German Center for Infection Research (DZIF), the consensus project brought together 20 professional organizations, two patient advocacy groups, regulatory authorities, and 18 international experts. The investigation sought to bridge key translation gaps by defining standardized protocols for strain matching, manufacturing, quality control, administration, and outcome documentation across clinical care settings.

The consensus panel established over 60 practice-oriented recommendations framed under the Association of the Scientific Medical Societies in Germany (AWMF) methodology, effective from January 5, 2026, through June 29, 2030. Observational benchmarks supporting personalized phage applications include a Belgian case series of 100 treated individuals, where clinical improvement was documented in 77% of patients and pathogen eradication occurred in 61% of cases. Clinical utility was further demonstrated at Frankfurt University Medical Center, where 10 patients received individualized phage treatments starting in February 2026 targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus via intravenous, inhalation, nasal spray, and sterile hydrogel routes.

The authors conclude that personalized phage therapy must be evaluated on a case-by-case basis through interdisciplinary boards rather than applied as a broad standard of care. Standardized “phage match” susceptibility testing, routine laboratory proficiency assessments, and centralized registry documentation are essential to ensure treatment quality. These harmonized guidelines establish the first inspection-ready global infrastructure for pharmacy preparation, clinical delivery, and regulatory oversight of personalized phage therapeutics.

Link to the article: https://www.nature.com/articles/s41591-026-04654-6

References

Würstle, S., Lieberknecht-Jouy, S. C., Düchting, A., Lößner, H., Ceyssens, P.-J., Pirnay, J.-P., de Jode, M., McCallin, S., Leitner, L., Willy, C., Leptihn, S., Korf, I., Idelevich, E. A., Witzenrath, M., Faltus, T., Ruth, P., Blume, H., Cornely, M., Fickenscher, H., … Classen, A. Y. (2026). A consensus-based guideline for personalized bacteriophage therapy. Nature Medicine, 1–17. https://doi.org/10.1038/s41591-026-04654-6